Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-IFNB
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intraperitoneal
01
Overview
MSC-IFNB is an investigational allogeneic cell and gene therapy consisting of mesenchymal stem cells (MSCs) genetically modified to express and secrete human interferon-beta (IFNB). Developed by researchers at MD Anderson Cancer Center, the therapy utilizes the innate ability of MSCs to home to and engraft within tumor stroma. By delivering a plasmid encoding IFNB via electroporation, the MSCs act as localized bioreactors that produce the cytokine directly at the tumor site. This targeted delivery is intended to maximize the anti-proliferative and immunomodulatory effects of IFNB—such as the recruitment of immune cells and direct induction of tumor cell death—while avoiding the systemic toxicities associated with high-dose recombinant interferon. Clinical evaluation has focused on the intraperitoneal administration of MSC-IFNB for patients with advanced, refractory epithelial ovarian cancer.
- Other names
- mesenchymal stem cells transfected with a plasmid secreting interferon betaIFN-beta-MSCsinterferon-beta-secreting mesenchymal stem cells
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on MSC-IFNB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-IFNB.